Cash and cash equivalents of $358.4 million as of March 31, 2025; projected revenues and cash expected to be sufficient to fund operations to profitability
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Qualcomm reinstated, Arista upgraded: Wall Street’s top analyst calls
- Apellis initiated with an Overweight at Cantor Fitzgerald
- Market Challenges and Revenue Dynamics Impacting Apellis Pharmaceuticals: A Hold Rating Analysis
- Hold Rating on Apellis Pharmaceuticals Amid Competitive Pressure from Astellas’ Izervay
- Buy Rating Affirmed for Apellis Pharmaceuticals Amid Market Expansion and Growth Prospects